Clinical Trial

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-02 -> 2027-08 2026-08-14
minor Completion pushed: 2026-02 -> 2027-08 2026-08-14
Trial Details
NCT Number NCT05276726
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions Non-small Cell Lung Cancer
Enrollment 104 participants
Start Date 2022-08-17
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-13